Decision on ovarian cancer drug olaparib is welcomed
The SMC approved the drug after hearing that patients tended to be younger women with family and work commitments.

Cancer Research UK said trials have shown that olaparib can extend lives by an average of seven months....

Read more : http://www.bbc.com/news/uk-scotland-37900200
Like
Comment
Share